'This is not a shotgun approach to dementia': Hospital execs share how they're rolling out Aduhelm

Hospitals are taking a cautious approach to rolling out aducanumab, Biogen's Alzheimer's drug sold under the brand name Aduhelm.

The FDA approved Aduhelm June 7, marking the first approval the agency has granted to an Alzheimer's treatment since 2003. It is the first treatment approved by the FDA intended to slow cognitive decline from Alzheimer's, as the Alzheimer's drugs the FDA has previously cleared are aimed at alleviating symptoms rather than slowing the disease's progression.